nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—stomach cancer	0.177	1	CbGaD
Fluoxetine—ABCB1—Mitomycin—stomach cancer	0.0735	0.171	CbGbCtD
Fluoxetine—CYP2B6—Irinotecan—stomach cancer	0.0368	0.0856	CbGbCtD
Fluoxetine—ALB—Irinotecan—stomach cancer	0.0361	0.0839	CbGbCtD
Fluoxetine—ALB—Fluorouracil—stomach cancer	0.0346	0.0805	CbGbCtD
Fluoxetine—CYP2C9—Capecitabine—stomach cancer	0.0315	0.0732	CbGbCtD
Fluoxetine—CYP3A5—Irinotecan—stomach cancer	0.029	0.0675	CbGbCtD
Fluoxetine—CYP3A5—Docetaxel—stomach cancer	0.0212	0.0494	CbGbCtD
Fluoxetine—CYP1A2—Fluorouracil—stomach cancer	0.0207	0.0482	CbGbCtD
Fluoxetine—CYP2B6—Doxorubicin—stomach cancer	0.0201	0.0468	CbGbCtD
Fluoxetine—ALB—Methotrexate—stomach cancer	0.0191	0.0444	CbGbCtD
Fluoxetine—ABCB1—Irinotecan—stomach cancer	0.0189	0.0439	CbGbCtD
Fluoxetine—CYP2C9—Fluorouracil—stomach cancer	0.0187	0.0434	CbGbCtD
Fluoxetine—ABCB1—Docetaxel—stomach cancer	0.0138	0.0322	CbGbCtD
Fluoxetine—CYP3A4—Irinotecan—stomach cancer	0.0113	0.0263	CbGbCtD
Fluoxetine—ABCB1—Doxorubicin—stomach cancer	0.0103	0.024	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—stomach cancer	0.00998	0.0232	CbGbCtD
Fluoxetine—CYP2D6—Doxorubicin—stomach cancer	0.00971	0.0226	CbGbCtD
Fluoxetine—ORM1—bile—stomach cancer	0.00905	0.141	CbGeAlD
Fluoxetine—CYP3A4—Docetaxel—stomach cancer	0.00828	0.0193	CbGbCtD
Fluoxetine—CYP3A4—Doxorubicin—stomach cancer	0.00617	0.0144	CbGbCtD
Fluoxetine—HTR2A—myenteric nerve plexus—stomach cancer	0.00589	0.0915	CbGeAlD
Fluoxetine—HTR2A—vagus nerve—stomach cancer	0.00393	0.061	CbGeAlD
Fluoxetine—HTR2A—vein—stomach cancer	0.00379	0.059	CbGeAlD
Fluoxetine—ORM1—gall bladder—stomach cancer	0.00251	0.039	CbGeAlD
Fluoxetine—ALB—gall bladder—stomach cancer	0.0022	0.0342	CbGeAlD
Fluoxetine—ORM1—hematopoietic system—stomach cancer	0.00142	0.0221	CbGeAlD
Fluoxetine—SLC6A4—hematopoietic system—stomach cancer	0.00121	0.0188	CbGeAlD
Fluoxetine—HTR2A—blood vessel—stomach cancer	0.0012	0.0187	CbGeAlD
Fluoxetine—SIGMAR1—smooth muscle tissue—stomach cancer	0.00106	0.0165	CbGeAlD
Fluoxetine—CYP2C19—hematopoietic system—stomach cancer	0.001	0.0156	CbGeAlD
Fluoxetine—SIGMAR1—pancreas—stomach cancer	0.00098	0.0152	CbGeAlD
Fluoxetine—ORM1—bone marrow—stomach cancer	0.000912	0.0142	CbGeAlD
Fluoxetine—SLC6A4—digestive system—stomach cancer	0.000843	0.0131	CbGeAlD
Fluoxetine—CYP1A2—hematopoietic system—stomach cancer	0.00082	0.0127	CbGeAlD
Fluoxetine—ORM1—endocrine gland—stomach cancer	0.000817	0.0127	CbGeAlD
Fluoxetine—CYP3A5—hematopoietic system—stomach cancer	0.000791	0.0123	CbGeAlD
Fluoxetine—ABCB1—blood vessel—stomach cancer	0.000789	0.0123	CbGeAlD
Fluoxetine—CYP2B6—hematopoietic system—stomach cancer	0.000786	0.0122	CbGeAlD
Fluoxetine—CYP2C9—hematopoietic system—stomach cancer	0.000778	0.0121	CbGeAlD
Fluoxetine—SIGMAR1—bone marrow—stomach cancer	0.000771	0.012	CbGeAlD
Fluoxetine—ORM1—liver—stomach cancer	0.000737	0.0114	CbGeAlD
Fluoxetine—CYP2C19—digestive system—stomach cancer	0.000698	0.0108	CbGeAlD
Fluoxetine—SLC6A4—endocrine gland—stomach cancer	0.000696	0.0108	CbGeAlD
Fluoxetine—ALB—liver—stomach cancer	0.000646	0.01	CbGeAlD
Fluoxetine—CYP3A5—pancreas—stomach cancer	0.000644	0.01	CbGeAlD
Fluoxetine—HTR2A—hematopoietic system—stomach cancer	0.000641	0.00996	CbGeAlD
Fluoxetine—SIGMAR1—liver—stomach cancer	0.000623	0.00969	CbGeAlD
Fluoxetine—SLC6A2—endocrine gland—stomach cancer	0.000613	0.00952	CbGeAlD
Fluoxetine—CYP3A4—hematopoietic system—stomach cancer	0.000594	0.00922	CbGeAlD
Fluoxetine—HTR2A—epithelium—stomach cancer	0.000586	0.00911	CbGeAlD
Fluoxetine—CYP2D6—hematopoietic system—stomach cancer	0.000584	0.00907	CbGeAlD
Fluoxetine—CYP2C19—endocrine gland—stomach cancer	0.000577	0.00896	CbGeAlD
Fluoxetine—CYP1A2—digestive system—stomach cancer	0.00057	0.00886	CbGeAlD
Fluoxetine—ORM1—lymph node—stomach cancer	0.000565	0.00878	CbGeAlD
Fluoxetine—HTR2A—smooth muscle tissue—stomach cancer	0.000565	0.00877	CbGeAlD
Fluoxetine—CYP2B6—lymphoid tissue—stomach cancer	0.000553	0.0086	CbGeAlD
Fluoxetine—CYP3A5—digestive system—stomach cancer	0.00055	0.00855	CbGeAlD
Fluoxetine—CYP2B6—digestive system—stomach cancer	0.000547	0.00849	CbGeAlD
Fluoxetine—CYP2C9—digestive system—stomach cancer	0.000541	0.00841	CbGeAlD
Fluoxetine—CYP2C19—liver—stomach cancer	0.00052	0.00808	CbGeAlD
Fluoxetine—ALB—lymph node—stomach cancer	0.000495	0.0077	CbGeAlD
Fluoxetine—SIGMAR1—lymph node—stomach cancer	0.000478	0.00743	CbGeAlD
Fluoxetine—CYP1A2—endocrine gland—stomach cancer	0.000471	0.00732	CbGeAlD
Fluoxetine—CYP3A5—endocrine gland—stomach cancer	0.000454	0.00706	CbGeAlD
Fluoxetine—CYP2B6—endocrine gland—stomach cancer	0.000452	0.00702	CbGeAlD
Fluoxetine—CYP2C9—endocrine gland—stomach cancer	0.000447	0.00695	CbGeAlD
Fluoxetine—HTR2A—digestive system—stomach cancer	0.000446	0.00693	CbGeAlD
Fluoxetine—CYP1A2—liver—stomach cancer	0.000425	0.0066	CbGeAlD
Fluoxetine—SLC6A2—lymph node—stomach cancer	0.000424	0.00658	CbGeAlD
Fluoxetine—ABCB1—hematopoietic system—stomach cancer	0.00042	0.00653	CbGeAlD
Fluoxetine—CYP3A4—digestive system—stomach cancer	0.000413	0.00641	CbGeAlD
Fluoxetine—CYP3A5—liver—stomach cancer	0.00041	0.00637	CbGeAlD
Fluoxetine—CYP2B6—liver—stomach cancer	0.000407	0.00633	CbGeAlD
Fluoxetine—CYP2D6—digestive system—stomach cancer	0.000406	0.00631	CbGeAlD
Fluoxetine—CYP2C9—liver—stomach cancer	0.000403	0.00627	CbGeAlD
Fluoxetine—ABCB1—epithelium—stomach cancer	0.000384	0.00597	CbGeAlD
Fluoxetine—HTR2A—endocrine gland—stomach cancer	0.000368	0.00572	CbGeAlD
Fluoxetine—ABCB1—pancreas—stomach cancer	0.000342	0.00532	CbGeAlD
Fluoxetine—CYP3A4—endocrine gland—stomach cancer	0.000341	0.0053	CbGeAlD
Fluoxetine—CYP2D6—endocrine gland—stomach cancer	0.000336	0.00521	CbGeAlD
Fluoxetine—HTR2A—liver—stomach cancer	0.000332	0.00516	CbGeAlD
Fluoxetine—CYP3A4—liver—stomach cancer	0.000308	0.00478	CbGeAlD
Fluoxetine—CYP2D6—liver—stomach cancer	0.000303	0.0047	CbGeAlD
Fluoxetine—ABCB1—lymphoid tissue—stomach cancer	0.000296	0.0046	CbGeAlD
Fluoxetine—ABCB1—digestive system—stomach cancer	0.000292	0.00454	CbGeAlD
Fluoxetine—ABCB1—bone marrow—stomach cancer	0.000269	0.00418	CbGeAlD
Fluoxetine—ABCB1—endocrine gland—stomach cancer	0.000241	0.00375	CbGeAlD
Fluoxetine—ABCB1—liver—stomach cancer	0.000218	0.00338	CbGeAlD
Fluoxetine—ABCB1—lymph node—stomach cancer	0.000167	0.00259	CbGeAlD
Fluoxetine—Insomnia—Docetaxel—stomach cancer	7.97e-05	0.000295	CcSEcCtD
Fluoxetine—Paraesthesia—Docetaxel—stomach cancer	7.91e-05	0.000292	CcSEcCtD
Fluoxetine—Erythema multiforme—Epirubicin—stomach cancer	7.91e-05	0.000292	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—stomach cancer	7.9e-05	0.000292	CcSEcCtD
Fluoxetine—Bradycardia—Doxorubicin—stomach cancer	7.88e-05	0.000291	CcSEcCtD
Fluoxetine—Dyspnoea—Docetaxel—stomach cancer	7.85e-05	0.00029	CcSEcCtD
Fluoxetine—Somnolence—Docetaxel—stomach cancer	7.83e-05	0.00029	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—stomach cancer	7.83e-05	0.000289	CcSEcCtD
Fluoxetine—Tinnitus—Epirubicin—stomach cancer	7.8e-05	0.000288	CcSEcCtD
Fluoxetine—Malnutrition—Methotrexate—stomach cancer	7.78e-05	0.000288	CcSEcCtD
Fluoxetine—Haemoglobin—Doxorubicin—stomach cancer	7.78e-05	0.000288	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Capecitabine—stomach cancer	7.77e-05	0.000287	CcSEcCtD
Fluoxetine—Vomiting—Fluorouracil—stomach cancer	7.76e-05	0.000287	CcSEcCtD
Fluoxetine—Rhinitis—Doxorubicin—stomach cancer	7.76e-05	0.000287	CcSEcCtD
Fluoxetine—Dyspepsia—Docetaxel—stomach cancer	7.76e-05	0.000287	CcSEcCtD
Fluoxetine—Haemorrhage—Doxorubicin—stomach cancer	7.74e-05	0.000286	CcSEcCtD
Fluoxetine—Hepatitis—Doxorubicin—stomach cancer	7.74e-05	0.000286	CcSEcCtD
Fluoxetine—Insomnia—Capecitabine—stomach cancer	7.72e-05	0.000285	CcSEcCtD
Fluoxetine—Hypoaesthesia—Doxorubicin—stomach cancer	7.7e-05	0.000285	CcSEcCtD
Fluoxetine—Rash—Fluorouracil—stomach cancer	7.7e-05	0.000285	CcSEcCtD
Fluoxetine—Dermatitis—Fluorouracil—stomach cancer	7.69e-05	0.000284	CcSEcCtD
Fluoxetine—Pharyngitis—Doxorubicin—stomach cancer	7.68e-05	0.000284	CcSEcCtD
Fluoxetine—Paraesthesia—Capecitabine—stomach cancer	7.66e-05	0.000283	CcSEcCtD
Fluoxetine—Decreased appetite—Docetaxel—stomach cancer	7.66e-05	0.000283	CcSEcCtD
Fluoxetine—Headache—Fluorouracil—stomach cancer	7.65e-05	0.000283	CcSEcCtD
Fluoxetine—Oedema peripheral—Doxorubicin—stomach cancer	7.62e-05	0.000282	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—stomach cancer	7.62e-05	0.000282	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Docetaxel—stomach cancer	7.61e-05	0.000281	CcSEcCtD
Fluoxetine—Dyspnoea—Capecitabine—stomach cancer	7.6e-05	0.000281	CcSEcCtD
Fluoxetine—Fatigue—Docetaxel—stomach cancer	7.6e-05	0.000281	CcSEcCtD
Fluoxetine—Nausea—Irinotecan—stomach cancer	7.57e-05	0.00028	CcSEcCtD
Fluoxetine—Pain—Docetaxel—stomach cancer	7.53e-05	0.000279	CcSEcCtD
Fluoxetine—Constipation—Docetaxel—stomach cancer	7.53e-05	0.000279	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—stomach cancer	7.53e-05	0.000278	CcSEcCtD
Fluoxetine—Dyspepsia—Capecitabine—stomach cancer	7.51e-05	0.000278	CcSEcCtD
Fluoxetine—Chills—Epirubicin—stomach cancer	7.51e-05	0.000277	CcSEcCtD
Fluoxetine—Arrhythmia—Epirubicin—stomach cancer	7.47e-05	0.000276	CcSEcCtD
Fluoxetine—Visual impairment—Doxorubicin—stomach cancer	7.46e-05	0.000276	CcSEcCtD
Fluoxetine—Decreased appetite—Capecitabine—stomach cancer	7.42e-05	0.000274	CcSEcCtD
Fluoxetine—Alopecia—Epirubicin—stomach cancer	7.39e-05	0.000273	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Capecitabine—stomach cancer	7.36e-05	0.000272	CcSEcCtD
Fluoxetine—Fatigue—Capecitabine—stomach cancer	7.35e-05	0.000272	CcSEcCtD
Fluoxetine—Mental disorder—Epirubicin—stomach cancer	7.33e-05	0.000271	CcSEcCtD
Fluoxetine—Erythema multiforme—Doxorubicin—stomach cancer	7.32e-05	0.000271	CcSEcCtD
Fluoxetine—Constipation—Capecitabine—stomach cancer	7.29e-05	0.00027	CcSEcCtD
Fluoxetine—Pain—Capecitabine—stomach cancer	7.29e-05	0.00027	CcSEcCtD
Fluoxetine—Malnutrition—Epirubicin—stomach cancer	7.28e-05	0.000269	CcSEcCtD
Fluoxetine—Feeling abnormal—Docetaxel—stomach cancer	7.26e-05	0.000268	CcSEcCtD
Fluoxetine—Nausea—Fluorouracil—stomach cancer	7.25e-05	0.000268	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—stomach cancer	7.22e-05	0.000267	CcSEcCtD
Fluoxetine—Tinnitus—Doxorubicin—stomach cancer	7.22e-05	0.000267	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Docetaxel—stomach cancer	7.2e-05	0.000266	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—stomach cancer	7.19e-05	0.000266	CcSEcCtD
Fluoxetine—Flatulence—Epirubicin—stomach cancer	7.17e-05	0.000265	CcSEcCtD
Fluoxetine—Tension—Epirubicin—stomach cancer	7.15e-05	0.000264	CcSEcCtD
Fluoxetine—Dysgeusia—Epirubicin—stomach cancer	7.13e-05	0.000264	CcSEcCtD
Fluoxetine—Nervousness—Epirubicin—stomach cancer	7.07e-05	0.000261	CcSEcCtD
Fluoxetine—Back pain—Epirubicin—stomach cancer	7.04e-05	0.00026	CcSEcCtD
Fluoxetine—Feeling abnormal—Capecitabine—stomach cancer	7.03e-05	0.00026	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—stomach cancer	7.02e-05	0.000259	CcSEcCtD
Fluoxetine—Muscle spasms—Epirubicin—stomach cancer	7e-05	0.000259	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—stomach cancer	6.99e-05	0.000258	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Capecitabine—stomach cancer	6.98e-05	0.000258	CcSEcCtD
Fluoxetine—Abdominal pain—Docetaxel—stomach cancer	6.96e-05	0.000257	CcSEcCtD
Fluoxetine—Body temperature increased—Docetaxel—stomach cancer	6.96e-05	0.000257	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—stomach cancer	6.96e-05	0.000257	CcSEcCtD
Fluoxetine—Chills—Doxorubicin—stomach cancer	6.94e-05	0.000257	CcSEcCtD
Fluoxetine—Arrhythmia—Doxorubicin—stomach cancer	6.91e-05	0.000256	CcSEcCtD
Fluoxetine—Alopecia—Doxorubicin—stomach cancer	6.84e-05	0.000253	CcSEcCtD
Fluoxetine—Cough—Methotrexate—stomach cancer	6.79e-05	0.000251	CcSEcCtD
Fluoxetine—Mental disorder—Doxorubicin—stomach cancer	6.78e-05	0.000251	CcSEcCtD
Fluoxetine—Urticaria—Capecitabine—stomach cancer	6.78e-05	0.000251	CcSEcCtD
Fluoxetine—Ill-defined disorder—Epirubicin—stomach cancer	6.76e-05	0.00025	CcSEcCtD
Fluoxetine—Abdominal pain—Capecitabine—stomach cancer	6.74e-05	0.000249	CcSEcCtD
Fluoxetine—Body temperature increased—Capecitabine—stomach cancer	6.74e-05	0.000249	CcSEcCtD
Fluoxetine—Convulsion—Methotrexate—stomach cancer	6.74e-05	0.000249	CcSEcCtD
Fluoxetine—Malnutrition—Doxorubicin—stomach cancer	6.74e-05	0.000249	CcSEcCtD
Fluoxetine—Anaemia—Epirubicin—stomach cancer	6.73e-05	0.000249	CcSEcCtD
Fluoxetine—Agitation—Epirubicin—stomach cancer	6.69e-05	0.000247	CcSEcCtD
Fluoxetine—Flatulence—Doxorubicin—stomach cancer	6.64e-05	0.000245	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—stomach cancer	6.62e-05	0.000245	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—stomach cancer	6.62e-05	0.000245	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—stomach cancer	6.62e-05	0.000245	CcSEcCtD
Fluoxetine—Tension—Doxorubicin—stomach cancer	6.61e-05	0.000244	CcSEcCtD
Fluoxetine—Dysgeusia—Doxorubicin—stomach cancer	6.6e-05	0.000244	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—stomach cancer	6.58e-05	0.000243	CcSEcCtD
Fluoxetine—Malaise—Epirubicin—stomach cancer	6.57e-05	0.000243	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—stomach cancer	6.54e-05	0.000242	CcSEcCtD
Fluoxetine—Nervousness—Doxorubicin—stomach cancer	6.54e-05	0.000242	CcSEcCtD
Fluoxetine—Vertigo—Epirubicin—stomach cancer	6.54e-05	0.000242	CcSEcCtD
Fluoxetine—Syncope—Epirubicin—stomach cancer	6.53e-05	0.000241	CcSEcCtD
Fluoxetine—Leukopenia—Epirubicin—stomach cancer	6.52e-05	0.000241	CcSEcCtD
Fluoxetine—Back pain—Doxorubicin—stomach cancer	6.52e-05	0.000241	CcSEcCtD
Fluoxetine—Hypersensitivity—Docetaxel—stomach cancer	6.49e-05	0.00024	CcSEcCtD
Fluoxetine—Muscle spasms—Doxorubicin—stomach cancer	6.48e-05	0.000239	CcSEcCtD
Fluoxetine—Palpitations—Epirubicin—stomach cancer	6.43e-05	0.000238	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—stomach cancer	6.4e-05	0.000237	CcSEcCtD
Fluoxetine—Loss of consciousness—Epirubicin—stomach cancer	6.4e-05	0.000237	CcSEcCtD
Fluoxetine—Cough—Epirubicin—stomach cancer	6.35e-05	0.000235	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—stomach cancer	6.35e-05	0.000235	CcSEcCtD
Fluoxetine—Asthenia—Docetaxel—stomach cancer	6.32e-05	0.000234	CcSEcCtD
Fluoxetine—Convulsion—Epirubicin—stomach cancer	6.31e-05	0.000233	CcSEcCtD
Fluoxetine—Infection—Methotrexate—stomach cancer	6.31e-05	0.000233	CcSEcCtD
Fluoxetine—Hypertension—Epirubicin—stomach cancer	6.29e-05	0.000232	CcSEcCtD
Fluoxetine—Hypersensitivity—Capecitabine—stomach cancer	6.28e-05	0.000232	CcSEcCtD
Fluoxetine—Ill-defined disorder—Doxorubicin—stomach cancer	6.25e-05	0.000231	CcSEcCtD
Fluoxetine—Pruritus—Docetaxel—stomach cancer	6.23e-05	0.00023	CcSEcCtD
Fluoxetine—Anaemia—Doxorubicin—stomach cancer	6.23e-05	0.00023	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—stomach cancer	6.22e-05	0.00023	CcSEcCtD
Fluoxetine—Arthralgia—Epirubicin—stomach cancer	6.2e-05	0.000229	CcSEcCtD
Fluoxetine—Myalgia—Epirubicin—stomach cancer	6.2e-05	0.000229	CcSEcCtD
Fluoxetine—Chest pain—Epirubicin—stomach cancer	6.2e-05	0.000229	CcSEcCtD
Fluoxetine—Agitation—Doxorubicin—stomach cancer	6.19e-05	0.000229	CcSEcCtD
Fluoxetine—Anxiety—Epirubicin—stomach cancer	6.18e-05	0.000228	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—stomach cancer	6.17e-05	0.000228	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—stomach cancer	6.16e-05	0.000228	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—stomach cancer	6.14e-05	0.000227	CcSEcCtD
Fluoxetine—Discomfort—Epirubicin—stomach cancer	6.12e-05	0.000226	CcSEcCtD
Fluoxetine—Asthenia—Capecitabine—stomach cancer	6.12e-05	0.000226	CcSEcCtD
Fluoxetine—Malaise—Doxorubicin—stomach cancer	6.08e-05	0.000225	CcSEcCtD
Fluoxetine—Dry mouth—Epirubicin—stomach cancer	6.06e-05	0.000224	CcSEcCtD
Fluoxetine—Vertigo—Doxorubicin—stomach cancer	6.05e-05	0.000224	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—stomach cancer	6.05e-05	0.000224	CcSEcCtD
Fluoxetine—Syncope—Doxorubicin—stomach cancer	6.04e-05	0.000223	CcSEcCtD
Fluoxetine—Pruritus—Capecitabine—stomach cancer	6.03e-05	0.000223	CcSEcCtD
Fluoxetine—Leukopenia—Doxorubicin—stomach cancer	6.03e-05	0.000223	CcSEcCtD
Fluoxetine—Diarrhoea—Docetaxel—stomach cancer	6.03e-05	0.000223	CcSEcCtD
Fluoxetine—Confusional state—Epirubicin—stomach cancer	5.99e-05	0.000222	CcSEcCtD
Fluoxetine—Palpitations—Doxorubicin—stomach cancer	5.95e-05	0.00022	CcSEcCtD
Fluoxetine—Anaphylactic shock—Epirubicin—stomach cancer	5.94e-05	0.00022	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—stomach cancer	5.93e-05	0.000219	CcSEcCtD
Fluoxetine—Loss of consciousness—Doxorubicin—stomach cancer	5.92e-05	0.000219	CcSEcCtD
Fluoxetine—Infection—Epirubicin—stomach cancer	5.9e-05	0.000218	CcSEcCtD
Fluoxetine—Cough—Doxorubicin—stomach cancer	5.88e-05	0.000217	CcSEcCtD
Fluoxetine—Shock—Epirubicin—stomach cancer	5.85e-05	0.000216	CcSEcCtD
Fluoxetine—Convulsion—Doxorubicin—stomach cancer	5.84e-05	0.000216	CcSEcCtD
Fluoxetine—Diarrhoea—Capecitabine—stomach cancer	5.84e-05	0.000216	CcSEcCtD
Fluoxetine—Dizziness—Docetaxel—stomach cancer	5.83e-05	0.000215	CcSEcCtD
Fluoxetine—Thrombocytopenia—Epirubicin—stomach cancer	5.82e-05	0.000215	CcSEcCtD
Fluoxetine—Hypertension—Doxorubicin—stomach cancer	5.82e-05	0.000215	CcSEcCtD
Fluoxetine—Tachycardia—Epirubicin—stomach cancer	5.8e-05	0.000214	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—stomach cancer	5.79e-05	0.000214	CcSEcCtD
Fluoxetine—Skin disorder—Epirubicin—stomach cancer	5.77e-05	0.000213	CcSEcCtD
Fluoxetine—Hyperhidrosis—Epirubicin—stomach cancer	5.74e-05	0.000212	CcSEcCtD
Fluoxetine—Insomnia—Methotrexate—stomach cancer	5.74e-05	0.000212	CcSEcCtD
Fluoxetine—Arthralgia—Doxorubicin—stomach cancer	5.74e-05	0.000212	CcSEcCtD
Fluoxetine—Myalgia—Doxorubicin—stomach cancer	5.74e-05	0.000212	CcSEcCtD
Fluoxetine—Chest pain—Doxorubicin—stomach cancer	5.74e-05	0.000212	CcSEcCtD
Fluoxetine—Anxiety—Doxorubicin—stomach cancer	5.72e-05	0.000211	CcSEcCtD
Fluoxetine—Paraesthesia—Methotrexate—stomach cancer	5.7e-05	0.000211	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—stomach cancer	5.7e-05	0.000211	CcSEcCtD
Fluoxetine—Discomfort—Doxorubicin—stomach cancer	5.67e-05	0.00021	CcSEcCtD
Fluoxetine—Anorexia—Epirubicin—stomach cancer	5.66e-05	0.000209	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—stomach cancer	5.66e-05	0.000209	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—stomach cancer	5.65e-05	0.000209	CcSEcCtD
Fluoxetine—Dizziness—Capecitabine—stomach cancer	5.64e-05	0.000209	CcSEcCtD
Fluoxetine—Dry mouth—Doxorubicin—stomach cancer	5.61e-05	0.000207	CcSEcCtD
Fluoxetine—Vomiting—Docetaxel—stomach cancer	5.6e-05	0.000207	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—stomach cancer	5.59e-05	0.000207	CcSEcCtD
Fluoxetine—Rash—Docetaxel—stomach cancer	5.56e-05	0.000205	CcSEcCtD
Fluoxetine—Hypotension—Epirubicin—stomach cancer	5.55e-05	0.000205	CcSEcCtD
Fluoxetine—Dermatitis—Docetaxel—stomach cancer	5.55e-05	0.000205	CcSEcCtD
Fluoxetine—Confusional state—Doxorubicin—stomach cancer	5.54e-05	0.000205	CcSEcCtD
Fluoxetine—Decreased appetite—Methotrexate—stomach cancer	5.52e-05	0.000204	CcSEcCtD
Fluoxetine—Headache—Docetaxel—stomach cancer	5.52e-05	0.000204	CcSEcCtD
Fluoxetine—Anaphylactic shock—Doxorubicin—stomach cancer	5.5e-05	0.000203	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Methotrexate—stomach cancer	5.48e-05	0.000203	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—stomach cancer	5.47e-05	0.000202	CcSEcCtD
Fluoxetine—Infection—Doxorubicin—stomach cancer	5.46e-05	0.000202	CcSEcCtD
Fluoxetine—Pain—Methotrexate—stomach cancer	5.43e-05	0.000201	CcSEcCtD
Fluoxetine—Vomiting—Capecitabine—stomach cancer	5.42e-05	0.000201	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Epirubicin—stomach cancer	5.41e-05	0.0002	CcSEcCtD
Fluoxetine—Shock—Doxorubicin—stomach cancer	5.41e-05	0.0002	CcSEcCtD
Fluoxetine—Thrombocytopenia—Doxorubicin—stomach cancer	5.38e-05	0.000199	CcSEcCtD
Fluoxetine—Rash—Capecitabine—stomach cancer	5.38e-05	0.000199	CcSEcCtD
Fluoxetine—Insomnia—Epirubicin—stomach cancer	5.37e-05	0.000199	CcSEcCtD
Fluoxetine—Dermatitis—Capecitabine—stomach cancer	5.37e-05	0.000199	CcSEcCtD
Fluoxetine—Tachycardia—Doxorubicin—stomach cancer	5.37e-05	0.000198	CcSEcCtD
Fluoxetine—Headache—Capecitabine—stomach cancer	5.34e-05	0.000198	CcSEcCtD
Fluoxetine—Skin disorder—Doxorubicin—stomach cancer	5.34e-05	0.000197	CcSEcCtD
Fluoxetine—Paraesthesia—Epirubicin—stomach cancer	5.34e-05	0.000197	CcSEcCtD
Fluoxetine—Hyperhidrosis—Doxorubicin—stomach cancer	5.32e-05	0.000197	CcSEcCtD
Fluoxetine—Dyspnoea—Epirubicin—stomach cancer	5.3e-05	0.000196	CcSEcCtD
Fluoxetine—Somnolence—Epirubicin—stomach cancer	5.28e-05	0.000195	CcSEcCtD
Fluoxetine—Anorexia—Doxorubicin—stomach cancer	5.24e-05	0.000194	CcSEcCtD
Fluoxetine—Nausea—Docetaxel—stomach cancer	5.23e-05	0.000193	CcSEcCtD
Fluoxetine—Feeling abnormal—Methotrexate—stomach cancer	5.23e-05	0.000193	CcSEcCtD
Fluoxetine—Dyspepsia—Epirubicin—stomach cancer	5.23e-05	0.000193	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—stomach cancer	5.19e-05	0.000192	CcSEcCtD
Fluoxetine—Decreased appetite—Epirubicin—stomach cancer	5.17e-05	0.000191	CcSEcCtD
Fluoxetine—Hypotension—Doxorubicin—stomach cancer	5.14e-05	0.00019	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Epirubicin—stomach cancer	5.13e-05	0.00019	CcSEcCtD
Fluoxetine—Fatigue—Epirubicin—stomach cancer	5.12e-05	0.000189	CcSEcCtD
Fluoxetine—Pain—Epirubicin—stomach cancer	5.08e-05	0.000188	CcSEcCtD
Fluoxetine—Constipation—Epirubicin—stomach cancer	5.08e-05	0.000188	CcSEcCtD
Fluoxetine—Nausea—Capecitabine—stomach cancer	5.07e-05	0.000187	CcSEcCtD
Fluoxetine—Urticaria—Methotrexate—stomach cancer	5.04e-05	0.000186	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—stomach cancer	5.02e-05	0.000186	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—stomach cancer	5.02e-05	0.000186	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Doxorubicin—stomach cancer	5.01e-05	0.000185	CcSEcCtD
Fluoxetine—Insomnia—Doxorubicin—stomach cancer	4.97e-05	0.000184	CcSEcCtD
Fluoxetine—Paraesthesia—Doxorubicin—stomach cancer	4.94e-05	0.000183	CcSEcCtD
Fluoxetine—Dyspnoea—Doxorubicin—stomach cancer	4.9e-05	0.000181	CcSEcCtD
Fluoxetine—Feeling abnormal—Epirubicin—stomach cancer	4.9e-05	0.000181	CcSEcCtD
Fluoxetine—Somnolence—Doxorubicin—stomach cancer	4.89e-05	0.000181	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Epirubicin—stomach cancer	4.86e-05	0.00018	CcSEcCtD
Fluoxetine—Dyspepsia—Doxorubicin—stomach cancer	4.84e-05	0.000179	CcSEcCtD
Fluoxetine—Decreased appetite—Doxorubicin—stomach cancer	4.78e-05	0.000177	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Doxorubicin—stomach cancer	4.75e-05	0.000175	CcSEcCtD
Fluoxetine—Fatigue—Doxorubicin—stomach cancer	4.74e-05	0.000175	CcSEcCtD
Fluoxetine—Urticaria—Epirubicin—stomach cancer	4.72e-05	0.000175	CcSEcCtD
Fluoxetine—Pain—Doxorubicin—stomach cancer	4.7e-05	0.000174	CcSEcCtD
Fluoxetine—Constipation—Doxorubicin—stomach cancer	4.7e-05	0.000174	CcSEcCtD
Fluoxetine—Abdominal pain—Epirubicin—stomach cancer	4.7e-05	0.000174	CcSEcCtD
Fluoxetine—Body temperature increased—Epirubicin—stomach cancer	4.7e-05	0.000174	CcSEcCtD
Fluoxetine—Hypersensitivity—Methotrexate—stomach cancer	4.68e-05	0.000173	CcSEcCtD
Fluoxetine—Asthenia—Methotrexate—stomach cancer	4.56e-05	0.000168	CcSEcCtD
Fluoxetine—Feeling abnormal—Doxorubicin—stomach cancer	4.53e-05	0.000168	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Doxorubicin—stomach cancer	4.5e-05	0.000166	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—stomach cancer	4.49e-05	0.000166	CcSEcCtD
Fluoxetine—Hypersensitivity—Epirubicin—stomach cancer	4.38e-05	0.000162	CcSEcCtD
Fluoxetine—Urticaria—Doxorubicin—stomach cancer	4.37e-05	0.000161	CcSEcCtD
Fluoxetine—Abdominal pain—Doxorubicin—stomach cancer	4.35e-05	0.000161	CcSEcCtD
Fluoxetine—Body temperature increased—Doxorubicin—stomach cancer	4.35e-05	0.000161	CcSEcCtD
Fluoxetine—Diarrhoea—Methotrexate—stomach cancer	4.34e-05	0.000161	CcSEcCtD
Fluoxetine—Asthenia—Epirubicin—stomach cancer	4.26e-05	0.000158	CcSEcCtD
Fluoxetine—Pruritus—Epirubicin—stomach cancer	4.2e-05	0.000155	CcSEcCtD
Fluoxetine—Dizziness—Methotrexate—stomach cancer	4.2e-05	0.000155	CcSEcCtD
Fluoxetine—Diarrhoea—Epirubicin—stomach cancer	4.07e-05	0.00015	CcSEcCtD
Fluoxetine—Hypersensitivity—Doxorubicin—stomach cancer	4.05e-05	0.00015	CcSEcCtD
Fluoxetine—Vomiting—Methotrexate—stomach cancer	4.04e-05	0.000149	CcSEcCtD
Fluoxetine—Rash—Methotrexate—stomach cancer	4e-05	0.000148	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—stomach cancer	4e-05	0.000148	CcSEcCtD
Fluoxetine—Headache—Methotrexate—stomach cancer	3.98e-05	0.000147	CcSEcCtD
Fluoxetine—Asthenia—Doxorubicin—stomach cancer	3.95e-05	0.000146	CcSEcCtD
Fluoxetine—Dizziness—Epirubicin—stomach cancer	3.93e-05	0.000145	CcSEcCtD
Fluoxetine—Pruritus—Doxorubicin—stomach cancer	3.89e-05	0.000144	CcSEcCtD
Fluoxetine—Vomiting—Epirubicin—stomach cancer	3.78e-05	0.00014	CcSEcCtD
Fluoxetine—Nausea—Methotrexate—stomach cancer	3.77e-05	0.000139	CcSEcCtD
Fluoxetine—Diarrhoea—Doxorubicin—stomach cancer	3.76e-05	0.000139	CcSEcCtD
Fluoxetine—Rash—Epirubicin—stomach cancer	3.75e-05	0.000139	CcSEcCtD
Fluoxetine—Dermatitis—Epirubicin—stomach cancer	3.74e-05	0.000138	CcSEcCtD
Fluoxetine—Headache—Epirubicin—stomach cancer	3.72e-05	0.000138	CcSEcCtD
Fluoxetine—Dizziness—Doxorubicin—stomach cancer	3.64e-05	0.000134	CcSEcCtD
Fluoxetine—Nausea—Epirubicin—stomach cancer	3.53e-05	0.00013	CcSEcCtD
Fluoxetine—Vomiting—Doxorubicin—stomach cancer	3.5e-05	0.000129	CcSEcCtD
Fluoxetine—Rash—Doxorubicin—stomach cancer	3.47e-05	0.000128	CcSEcCtD
Fluoxetine—Dermatitis—Doxorubicin—stomach cancer	3.46e-05	0.000128	CcSEcCtD
Fluoxetine—Headache—Doxorubicin—stomach cancer	3.44e-05	0.000127	CcSEcCtD
Fluoxetine—Nausea—Doxorubicin—stomach cancer	3.27e-05	0.000121	CcSEcCtD
Fluoxetine—CYP2C9—Metabolism—CYP2A6—stomach cancer	7.69e-06	0.000131	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	7.66e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTP1—stomach cancer	7.65e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALOX5—stomach cancer	7.64e-06	0.000131	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—AKR1C3—stomach cancer	7.54e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—HMOX1—stomach cancer	7.54e-06	0.000129	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—DPYD—stomach cancer	7.52e-06	0.000129	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL8—stomach cancer	7.51e-06	0.000128	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—AKR1C3—stomach cancer	7.48e-06	0.000128	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—FGFR2—stomach cancer	7.45e-06	0.000127	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—RHOA—stomach cancer	7.43e-06	0.000127	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ENO1—stomach cancer	7.35e-06	0.000126	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMP—stomach cancer	7.32e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—FADS1—stomach cancer	7.32e-06	0.000125	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—ALB—stomach cancer	7.3e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ENO1—stomach cancer	7.29e-06	0.000125	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—TYMS—stomach cancer	7.27e-06	0.000124	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SMAD4—stomach cancer	7.26e-06	0.000124	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—GSTM1—stomach cancer	7.19e-06	0.000123	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—stomach cancer	7.19e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—stomach cancer	7.17e-06	0.000123	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—TYMS—stomach cancer	7.11e-06	0.000122	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CD44—stomach cancer	7.09e-06	0.000121	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—GSTM1—stomach cancer	7.03e-06	0.00012	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CD44—stomach cancer	6.92e-06	0.000118	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FYN—stomach cancer	6.89e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	6.88e-06	0.000118	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—SREBF2—stomach cancer	6.85e-06	0.000117	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IRS2—stomach cancer	6.83e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—stomach cancer	6.81e-06	0.000117	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—RORA—stomach cancer	6.77e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ERCC2—stomach cancer	6.76e-06	0.000116	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPP2R1A—stomach cancer	6.72e-06	0.000115	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTT1—stomach cancer	6.65e-06	0.000114	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—stomach cancer	6.63e-06	0.000113	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CAV1—stomach cancer	6.62e-06	0.000113	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ERCC2—stomach cancer	6.61e-06	0.000113	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOA1—stomach cancer	6.6e-06	0.000113	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTP1—stomach cancer	6.59e-06	0.000113	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2A6—stomach cancer	6.57e-06	0.000112	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—stomach cancer	6.52e-06	0.000112	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CD44—stomach cancer	6.52e-06	0.000112	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—HMOX1—stomach cancer	6.5e-06	0.000111	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—FGFR2—stomach cancer	6.47e-06	0.000111	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CD44—stomach cancer	6.46e-06	0.000111	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—AKR1C3—stomach cancer	6.39e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—MTHFR—stomach cancer	6.36e-06	0.000109	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALDOB—stomach cancer	6.34e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PRKCB—stomach cancer	6.3e-06	0.000108	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6ST—stomach cancer	6.27e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	6.27e-06	0.000107	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK3—stomach cancer	6.27e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ENO1—stomach cancer	6.23e-06	0.000107	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—MTHFR—stomach cancer	6.21e-06	0.000106	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—stomach cancer	6.13e-06	0.000105	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—TYMS—stomach cancer	6.12e-06	0.000105	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—GSTM1—stomach cancer	6.05e-06	0.000104	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPP2R1A—stomach cancer	6.03e-06	0.000103	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APC—stomach cancer	6.03e-06	0.000103	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—MAPK1—stomach cancer	5.97e-06	0.000102	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IRS2—stomach cancer	5.93e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTP1—stomach cancer	5.91e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALOX5—stomach cancer	5.9e-06	0.000101	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPP2R1A—stomach cancer	5.88e-06	0.000101	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CAV1—stomach cancer	5.86e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOA1—stomach cancer	5.85e-06	0.0001	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—HMOX1—stomach cancer	5.83e-06	9.97e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—DPYD—stomach cancer	5.8e-06	9.92e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK3—stomach cancer	5.77e-06	9.87e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTP1—stomach cancer	5.77e-06	9.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CAV1—stomach cancer	5.75e-06	9.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOA1—stomach cancer	5.73e-06	9.8e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAV1—stomach cancer	5.73e-06	9.8e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOA1—stomach cancer	5.72e-06	9.78e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—HMOX1—stomach cancer	5.69e-06	9.73e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—ERCC2—stomach cancer	5.69e-06	9.73e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—KRAS—stomach cancer	5.64e-06	9.64e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6R—stomach cancer	5.6e-06	9.57e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPP2R1A—stomach cancer	5.54e-06	9.48e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CD44—stomach cancer	5.52e-06	9.45e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—TYMS—stomach cancer	5.5e-06	9.4e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPP2R1A—stomach cancer	5.5e-06	9.4e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—MAPK1—stomach cancer	5.49e-06	9.39e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—EGFR—stomach cancer	5.49e-06	9.39e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PRKCB—stomach cancer	5.47e-06	9.35e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6ST—stomach cancer	5.45e-06	9.32e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTP1—stomach cancer	5.44e-06	9.3e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—GSTM1—stomach cancer	5.43e-06	9.29e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTP1—stomach cancer	5.39e-06	9.22e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—TYMS—stomach cancer	5.37e-06	9.18e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—HMOX1—stomach cancer	5.36e-06	9.17e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—stomach cancer	5.36e-06	9.17e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—MTHFR—stomach cancer	5.35e-06	9.15e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—HMOX1—stomach cancer	5.32e-06	9.09e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—GSTM1—stomach cancer	5.3e-06	9.07e-05	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—PIK3CA—stomach cancer	5.25e-06	8.98e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SERPINE1—stomach cancer	5.24e-06	8.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APC—stomach cancer	5.23e-06	8.95e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—KRAS—stomach cancer	5.19e-06	8.87e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—PIK3CA—stomach cancer	5.18e-06	8.86e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—stomach cancer	5.15e-06	8.81e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTT1—stomach cancer	5.13e-06	8.77e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ERCC2—stomach cancer	5.11e-06	8.74e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2A6—stomach cancer	5.07e-06	8.67e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—TYMS—stomach cancer	5.06e-06	8.65e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—RHOA—stomach cancer	5.06e-06	8.65e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—stomach cancer	5.04e-06	8.61e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK3—stomach cancer	5.01e-06	8.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—TYMS—stomach cancer	5.01e-06	8.57e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—stomach cancer	5.01e-06	8.57e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NOS3—stomach cancer	5e-06	8.56e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—GSTM1—stomach cancer	5e-06	8.55e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ERCC2—stomach cancer	4.99e-06	8.53e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—GSTM1—stomach cancer	4.95e-06	8.47e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAV1—stomach cancer	4.93e-06	8.44e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—AKR1C3—stomach cancer	4.93e-06	8.44e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOA1—stomach cancer	4.92e-06	8.42e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6R—stomach cancer	4.86e-06	8.31e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ENO1—stomach cancer	4.81e-06	8.22e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—MTHFR—stomach cancer	4.8e-06	8.21e-05	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—HRAS—stomach cancer	4.79e-06	8.19e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—MAPK1—stomach cancer	4.77e-06	8.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—EGFR—stomach cancer	4.77e-06	8.16e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—PIK3CA—stomach cancer	4.77e-06	8.15e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.71e-06	8.06e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ERCC2—stomach cancer	4.7e-06	8.04e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPP2R1A—stomach cancer	4.7e-06	8.03e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—MTHFR—stomach cancer	4.69e-06	8.02e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—ERBB2—stomach cancer	4.68e-06	8e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ERCC2—stomach cancer	4.66e-06	7.97e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—ALB—stomach cancer	4.63e-06	7.92e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTP1—stomach cancer	4.61e-06	7.88e-05	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—PIK3CA—stomach cancer	4.56e-06	7.79e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SERPINE1—stomach cancer	4.55e-06	7.78e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—HMOX1—stomach cancer	4.54e-06	7.77e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—ALB—stomach cancer	4.53e-06	7.75e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—KRAS—stomach cancer	4.51e-06	7.7e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—stomach cancer	4.44e-06	7.59e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NOS3—stomach cancer	4.43e-06	7.58e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAV1—stomach cancer	4.43e-06	7.57e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOA1—stomach cancer	4.42e-06	7.56e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—MTHFR—stomach cancer	4.42e-06	7.55e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HRAS—stomach cancer	4.41e-06	7.54e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—RHOA—stomach cancer	4.39e-06	7.51e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—MTHFR—stomach cancer	4.38e-06	7.49e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NOS3—stomach cancer	4.35e-06	7.43e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—stomach cancer	4.34e-06	7.42e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1B—stomach cancer	4.33e-06	7.41e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NOS3—stomach cancer	4.33e-06	7.41e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAV1—stomach cancer	4.32e-06	7.39e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOA1—stomach cancer	4.31e-06	7.38e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—TYMS—stomach cancer	4.28e-06	7.32e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CD44—stomach cancer	4.26e-06	7.29e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—GSTM1—stomach cancer	4.23e-06	7.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	4.23e-06	7.24e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—stomach cancer	4.22e-06	7.22e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—PIK3CA—stomach cancer	4.14e-06	7.08e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCND1—stomach cancer	4.14e-06	7.07e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—stomach cancer	4.13e-06	7.06e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAV1—stomach cancer	4.07e-06	6.97e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOA1—stomach cancer	4.07e-06	6.95e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—ERBB2—stomach cancer	4.06e-06	6.95e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PTGS2—stomach cancer	4.05e-06	6.93e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAV1—stomach cancer	4.04e-06	6.91e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOA1—stomach cancer	4.03e-06	6.89e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MMP9—stomach cancer	4.01e-06	6.87e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CDKN1A—stomach cancer	4e-06	6.84e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ERCC2—stomach cancer	3.98e-06	6.81e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PTGS2—stomach cancer	3.96e-06	6.78e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK8—stomach cancer	3.9e-06	6.68e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—stomach cancer	3.89e-06	6.66e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.86e-06	6.6e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—stomach cancer	3.85e-06	6.59e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HRAS—stomach cancer	3.83e-06	6.55e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—stomach cancer	3.8e-06	6.5e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1B—stomach cancer	3.76e-06	6.44e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—MTHFR—stomach cancer	3.74e-06	6.4e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—NOS3—stomach cancer	3.73e-06	6.38e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—stomach cancer	3.67e-06	6.27e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPP2R1A—stomach cancer	3.63e-06	6.2e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—stomach cancer	3.6e-06	6.16e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCND1—stomach cancer	3.59e-06	6.14e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—stomach cancer	3.58e-06	6.13e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—stomach cancer	3.58e-06	6.12e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—stomach cancer	3.57e-06	6.1e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTP1—stomach cancer	3.56e-06	6.08e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—stomach cancer	3.55e-06	6.07e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—HMOX1—stomach cancer	3.51e-06	6e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—ALB—stomach cancer	3.5e-06	5.99e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MMP9—stomach cancer	3.49e-06	5.96e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CDKN1A—stomach cancer	3.47e-06	5.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAV1—stomach cancer	3.45e-06	5.9e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOA1—stomach cancer	3.44e-06	5.89e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—ALB—stomach cancer	3.42e-06	5.84e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PTGS2—stomach cancer	3.41e-06	5.84e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK3—stomach cancer	3.41e-06	5.83e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK8—stomach cancer	3.39e-06	5.8e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—NOS3—stomach cancer	3.35e-06	5.73e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MYC—stomach cancer	3.32e-06	5.67e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—TYMS—stomach cancer	3.31e-06	5.65e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—stomach cancer	3.3e-06	5.64e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NOS3—stomach cancer	3.27e-06	5.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—GSTM1—stomach cancer	3.27e-06	5.59e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—MAPK1—stomach cancer	3.24e-06	5.55e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—EGFR—stomach cancer	3.24e-06	5.55e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—ALB—stomach cancer	3.22e-06	5.51e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—ALB—stomach cancer	3.19e-06	5.46e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—stomach cancer	3.13e-06	5.35e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—stomach cancer	3.1e-06	5.3e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NOS3—stomach cancer	3.08e-06	5.27e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ERCC2—stomach cancer	3.07e-06	5.25e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—KRAS—stomach cancer	3.06e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PTGS2—stomach cancer	3.06e-06	5.24e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NOS3—stomach cancer	3.05e-06	5.22e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—stomach cancer	3.03e-06	5.19e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PTGS2—stomach cancer	2.99e-06	5.11e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK3—stomach cancer	2.96e-06	5.06e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—MTHFR—stomach cancer	2.89e-06	4.94e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MYC—stomach cancer	2.88e-06	4.93e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—MAPK1—stomach cancer	2.82e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PTGS2—stomach cancer	2.82e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—EGFR—stomach cancer	2.82e-06	4.82e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—PIK3CA—stomach cancer	2.82e-06	4.81e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PTGS2—stomach cancer	2.79e-06	4.78e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—ALB—stomach cancer	2.73e-06	4.67e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—stomach cancer	2.72e-06	4.66e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAV1—stomach cancer	2.66e-06	4.56e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—KRAS—stomach cancer	2.66e-06	4.55e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOA1—stomach cancer	2.66e-06	4.54e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NOS3—stomach cancer	2.61e-06	4.46e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—HRAS—stomach cancer	2.61e-06	4.45e-05	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PIK3CA—stomach cancer	2.49e-06	4.27e-05	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—stomach cancer	2.49e-06	4.26e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—PIK3CA—stomach cancer	2.45e-06	4.18e-05	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PIK3CA—stomach cancer	2.44e-06	4.17e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PTGS2—stomach cancer	2.39e-06	4.08e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—stomach cancer	2.37e-06	4.04e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—stomach cancer	2.34e-06	4e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—HRAS—stomach cancer	2.26e-06	3.87e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—stomach cancer	2.17e-06	3.7e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—ALB—stomach cancer	2.11e-06	3.6e-05	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PIK3CA—stomach cancer	2.1e-06	3.59e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NOS3—stomach cancer	2.01e-06	3.44e-05	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PIK3CA—stomach cancer	1.88e-06	3.22e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PTGS2—stomach cancer	1.84e-06	3.15e-05	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PIK3CA—stomach cancer	1.84e-06	3.15e-05	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PIK3CA—stomach cancer	1.73e-06	2.96e-05	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PIK3CA—stomach cancer	1.72e-06	2.94e-05	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PIK3CA—stomach cancer	1.47e-06	2.51e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PIK3CA—stomach cancer	1.13e-06	1.94e-05	CbGpPWpGaD
